1353563-85-5

AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1].

AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a novel immune checkpoint modulator, is an inhibitor of PD-1 signaling pathway.

In hPDL2-expressing HEK293 cells, AUNP-12 inhibited the binding of PD1 to PDL2 with EC50 of 0.72 nM; in hPDL1-expressing MDA-MB231 cells, in PBMC proliferation assay, EC50 was 0.41 nM.

Target	Value
PD-L1 (Cell-free assay)

[1] Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091. DOI:10.1158/1535-7163.MCT-18-0737